FDA denies approval of follow-on Lovenox

The FDA rejected Novartis AG's and Momenta Pharmaceuticals' follow-on version of the anti-clotting drug Lovenox because of concerns about the treatment's possible effect on the immune system. Momenta CEO Craig Wheeler said the FDA could ask that Momenta conduct additional clinical trials of the drug.

View Full Article in:

Boston Globe (tiered subscription model), The · Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Chief, Product Review Branch
FDA/Center for Biologics Evaluation and Research
Silver Spring, MD
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ